

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/574,046
				Filing Date	1/31/07
				First Named Inventor	Dickey
				Art Unit	1646
				Examiner Name	B. Hissong
Sheet	1	of	3	Attorney Docket Number	040989/309915

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/BH/	25	US-4,956,282	09/11/1990	Goodman <i>et al.</i>	
	26	US-5,550,038	08/27/1996	Goodman <i>et al.</i>	
	27	US-5,629,175	05/13/1997	Goodman <i>et al.</i>	
	28	US-6,096,547	08/01/2000	Goodman <i>et al.</i>	
	29	US-6,610,830	08/26/2003	Goeddel <i>et al.</i>	
	30	US-6,774,283	08/10/2004	Goodman <i>et al.</i>	
	31	US-2003/0167531	09/04/2003	Russell, et al.	
	32	US-2004/0219131	11/04/2004	Patten et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/BH/	33	AT 393690 B	11/25/1991	Hoffman La Roche (CH)		
	34	EP 0032134 B2	07/15/1981	Weissmann, et al.		
	35	EP 0141484 A2	05/15/1985	Weissmann, et al.		
	36	EP 0 194 006 A1	09/10/1986	Imperial Chemical Industries PLC		
	37	EP 0 256 424 A1	02/24/1988	Hoffmann-La Roche & Co.		
	38	WO 01/36001 A2	05/25/2001	Maxygen APS [DK]		
	39	WO 03/002152 A2	01/09/2003	Maxygen APS [DK]		
	40	WO 2004/046365 A2	06/03/2004	Maxygen Inc.		

Examiner Signature	/Bruce Hissong/	Date Considered	01/29/2011
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/574,046
				Filing Date	1/31/07
				First Named Inventor	Dickey
				Art Unit	1646
				Examiner Name	B. Hissong
Sheet	2	of	3	Attorney Docket Number	040989/309915

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BH/ ↓ ↓ ↓ ↓ ↓	41	CHANG, et al., "Evolution of a cytokine using DNA family shuffling", <u>Nature Biotech.</u> (1999) 17:793-797	
	42	DÖBELI, H. <i>et al.</i> , "Role of the carboxyl-terminal sequence on the biological activity of human immune interferon (IFN-Gamma)," <i>Journal of Biotechnology</i> , 1988, Vol. 7(3), pp. 199-216.	
	43	HORISBERGER, M. et al., "Interferon-Alpha Hybrids," <i>Pharmacology & Therapeutics</i> , 1995, Vol. 66(3), pp. 507-534.	
	44	HOUGHTON, "Human Interferon Gene Sequences," <i>Nature</i> , 1980, Vol. 285(5766), pp. 536	
	45	MANTEI, et al., "The nucleotide sequence of a cloned human leukocyte interferon cDNA", <u>Gene</u> (1980) 10:1-10	
	46	MANTEI, et al., "The nucleotide sequence of a cloned human leukocyte interferon cDNA", <u>Chemical Abstracts</u> (1980) 93:489, Abstract No. 130319s	

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BH/ ↓ ↓ ↓ ↓ ↓ ↓	47	NACHEVA, G. <i>et al.</i> , "Human interferon gamma: significance of the C-terminal flexible domain for its biological activity," <i>Archives of Biochemistry and Biophysics</i> , 2003, Vol. 413(1), pp. 91-98l.	
	48	NAGATA, et al., "The structure of one of the eight or more distinct chromosomal genes for human interfereferon-alpha", <u>Nature</u> (1980) 287(5781):401-408	
	49	NAGATA, et al., "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity", <u>Chemical Abstracts</u> (1980) 93:479, Abstract No. 41286m	
	50	NAGATA, et al., "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity", <u>Nature</u> (1980) 284:316-320	
	51	OZES, et al., "A comparison of Interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities", <u>J. Interferon Res.</u> (1992) 12:55-59	
	52	PESTKA and LANGER, "Interferons and their actions", <u>Ann. Rev. Biochem.</u> (1987) 56:727-77	
	53	PLATIS and FOSTER, "High yield expression, refolding, and characterization of recombinant interferon α2/α8 hybrids in <i>Escherichia coli</i> ", <u>Protein Expression and Purification</u> (2003) 31:222-230	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Bruce Hissong/	Date Considered	01/29/2011
--------------------	-----------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/574,046
				Filing Date	1/31/07
				First Named Inventor	Dickey
				Art Unit	1646
				Examiner Name	B. Hissong
Sheet	3	of	3	Attorney Docket Number	040989/309915

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BH/	54	RUBINSTEIN, et al., "Human leukocyte interferon: isolation and characterization of several molecular forms", <u>Arch. of Biochem. and Biophysics</u> (1981) 210:307-318	
	55	RUBINSTEIN, et al., "Human leukocyte interferon purified to homogeneity", <u>Science</u> (1978) 202(4374):1289-1290	
	56	RUBINSTEIN, et al., "Human leukocyte interferon: production, purification to homogeneity, and initial characterization", <u>Proc. Natl. Acad. Sci. USA</u> (1979) 76(2):640-644	
	57	SCHILLIBERG, et al., "Review – Molecular Farming of Recombinant Antibodies in Plants," (2003) <u>CMLA, Cell. Mol. Life Sci.</u> 60:433-445	
	58	STREULI, et al., "At least three human type alpha interferons: structure of alpha 2", <u>Science</u> (1980) 209(4463):1343-1347	
	59	SUGIYAMA, et al., "Expression of Human Interferon-a2 in Sf9 Cells," <u>Dur. J. Biochem.</u> (1993) 271:921-927	
	60	TANIGUCHI, et al., "Expression of the Human Fibroblast Interferon Gene in Escherichia coli", <u>Proc. Natl. Acad. Sci. USA</u> (1980) 77(9):5230-5233	
	61	TANIGUCHI, et al., "Human leukocyte and fibroblast interferons are structurally related", <u>Nature</u> (1980) 285:547-549	
	62	TORMA and PAUCKER, "Purification and characterization of human leukocyte interferon components", <u>J. Biol. Chem.</u> (1976) 251(16):4810-4816	
	63	WEISSMANN, "The cloning of interferon and other mistakes", <u>Interferon</u> (1981) 3:101-134	
	64	ZOON, et al., "Amino terminal sequence of the major component of human lymphoblastoid interferon", <u>Science</u> (1980) 207(4430):527-528	
	65	ZOON, et al., "Purification and partial characterization of human lymphoblastoid interferon", <u>Proc. Natl. Acad. Sci. USA</u> (1979) 76(11):5601-5605	
	66	ZOON, et al., "Human lymphoblastoid interferon: purification, amino acid composition, and amino-terminal sequence", <u>Ann. NY Acad. Sci.</u> (1980) 350:390-398	
	67	ZHU, et al., "Expression of Human a-Interferon cDNA in Transgenic Rice Plants," <u>Plant Cell, Tissue and Organ Culture</u> (1994) 36:197-204	

Examiner Signature	/Bruce Hissong/	Date Considered	01/29/2011
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT AND TRADEMARK OFFICE ON NOVEMBER 4, 2010.

LEGAL02/32257953v1